Editas Medicine, Inc. expected to post a loss of 27 cents a share - Earnings Preview

Editas Medicine

07/08/2026 15:33

Editas Medicine, Inc. EDIT.OQ EDIT.O is expected to  show a fall in quarterly revenue when it reports  results  for the period ending September 30 2026
The Cambridge Massachusetts-based  company is expected to report a 54.5% decrease in revenue to $3.429 million from $7.54 million a year ago, according to the mean estimate from 10 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Editas Medicine, Inc. is for a loss of 27 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 3 "hold" and 2 "sell" or "strong sell."  
The mean earnings estimate of analysts had fallen by about 2.4% in the last three months. ​
Wall Street's median 12-month price target for Editas Medicine, Inc. is $5.00, about 72.4% above its last closing price of $2.90
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2026
-0.28
-0.27
-0.15
Beat
44.4
Mar. 31 2026
-0.27
-0.26
-0.26
Met
1.4
Dec. 31 2025
-0.25
-0.26
-0.06
Beat
76.8​
Sep. 30 2025
-0.30
-0.30
-0.28
Beat
5.5
​​Jun. 30 2025
-0.37
-0.38
-0.63
Missed
-67.1
Mar. 31 2025
-0.61
-0.59
-0.92
Missed
-56.2​
Dec. 31 2024
-0.19
-0.36
-0.55
Missed
-54.2
Sep. 30 2024
-0.72
-0.75
-0.75
Met
-0.4
This summary was machine generated August 7 at 14:33 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)